Introduction
Interactions between genetic and environmental factors are thought to play important roles in the pathogenesis of hypertension. The use of association studies in large epidemiological cohorts with a large number of single-nucleotide polymorphisms throughout the entire genome or throughout a single gene is a new strategy for identifying genes that contribute to blood pressure regulation (1) (2) (3) . In the present study, we applied this strategy to the norepinephrine transporter gene (solute carrier family 6, member 2; SLC6A2) to examine whether its genetic variants influence blood pressure.
reboxetine has been reported to induce a slight but significant increase in blood pressure (6) . More direct evidence that the neuronal reuptake of norepinephrine is impaired in essential hypertension has also been reported (7) . Thus, SLC6A2 is a good candidate gene for human essential hypertension.
In the present study, we thoroughly searched for polymorphisms of SLC6A2 and performed an association study using a large epidemiological cohort. To our knowledge, this is the first report to investigate associations between SLC6A2 genetic variants and blood pressure.
Methods

Subjects
The selection criteria and design of the Suita study have been described previously (2) . The present study was approved by the Ethics Committee of the National Cardiovascular Center and by the Committee on Genetic Analysis and Genetic Therapy of the National Cardiovascular Center. Written informed consent for genetic analysis was obtained from about 3,700 subjects, and the genotype of SLC6A2 was determined in 1,950 consecutive subjects. Subjects were categorized as hypertensives when they had a systolic blood pressure of 140 mmHg or a diastolic blood pressure of 90 mmHg. Subjects who were taking hypertensive medication were also categorized as hypertensives.
DNA Studies
DNA was isolated from peripheral leukocytes according to standard procedures. Genomic DNA from 24 subjects was used as a template for sequence analyses. The promoter (up to 1.5 kb) and coding regions (exons 1-14) were sequenced. Polymorphisms were determined by the TaqMan system. The results were analyzed using an ABI PRISM 7700 Sequence Detection System (PE Biosystems, Foster City, USA) using allelic discrimination software supplied by the manufacturer.
Statistical Analyses
Values are expressed as the mean SEM. All statistical analyses were performed with the JMP statistical package (SAS Institute Inc., Cary, USA). Multiple regression and multiple logistic analyses were performed with other covariates. The effects of polymorphisms on blood pressure and heart rate were assessed in subjects who were not receiving cardiovascular medications, since hypertensive subjects with excellent blood pressure control by medication may have normal blood pressure values. We excluded subjects who were receiving antihypertensive treatment, subjects who had had cerebrovascular accidents, subjects with demonstrated ischemic heart disease, and subjects with atrial fibrillation. Residuals of blood pressure values were calculated by adjusting for sex, age, ethanol consumption, and body mass index (BMI) (residuals of blood pressure values were the observed values minus the values predicted based on the sex, age, ethanol consumption, and BMI). Residuals of heart rate were calculated by adjusting for sex. Data was analyzed using a contingency table analysis and one-way analysis of variance (ANOVA) with Bonferroni correction for multiple comparisons. The sample power was calculated using SPSS software (SPSS Inc., Chicago, USA).
Results
Detection of Genetic Variants
We sequenced the promoter region (up to 1.5kb) and coding regions (exons 1-14) and found 9 polymorphisms in SLC6A2 ( Table 1) . Promoter 1, 4, and 5 polymorphisms were in complete disequilibrium among the 24 subjects sequenced, and the Promoter 1 polymorphism was selected for the association study. Intron 8, exon 9, and intron 13 polymorphisms were in tight linkage disequilibrium (45/48 93.75% could be explained by the two haplotypes) among the 24 subjects sequenced, and the Intron 8 polymorphism was selected for the association study. Promoter 2, Promoter 3, and intron 5 were not in linkage disequilibrium with the others and were selected for the association study. The primers and probes for genotype determination are summarized in Table 2 . No missense mutation was found in the exonic regions.
Association Study
An association study between the polymorphisms and blood pressure status revealed that only the Promoter 3 polymorphism had significant effects on the frequency of hypertension (Table 3) . Table 4 shows characteristics of the study population according to the Promoter 3 genotype. The frequencies of the AG and GG genotypes in the Promoter 3 polymorphism were higher among hypertensives. When blood pressure values were adjusted for sex, age, BMI, and 
Sample Power Calculation
The sample power in the present study was 0.79 for the distribution, sample size, and α value (0.05, two-tailed).
Discussion
At most synapses, chemical signaling is terminated by a rapid reaccumulation of neurotransmitters into presynaptic terminals. The reuptake of noradrenaline occurs via a specific Na -and Cl -dependent transport system which is the target for tricyclic antidepressants such as desipramine and imipramine. Pacholczyk et al. isolated a cDNA encoding a human noradrenaline transporter (SLC6A2) (8) . The cDNA sequence predicted a protein of 617 amino acids, with 12-13 highly hydrophobic regions compatible with membranespanning domains. They also suggested that analysis of the
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Genotype frequency (n 1,950) indicates the percentages of homozygotes having the major allele : heterozygotes : homozygotes with the minor allele. HTN, hypertensive subjects; NT, normotensive subjects structure and function of this transporter may aid structurebased drug design for the treatment of human depression and lead to a determination of whether transporter abnormalities underlie affective disorders. Genetic dysfunction of SLC6A2 has been reported to cause idiopathic orthostatic intolerance, which is a syndrome characterized by lightheadedness, fatigue, altered mentation, and syncope, and is associated with postural tachycardia and plasma norepinephrine concentrations that are disproportionately high in relation to sympathetic outflow (4).
Interestingly, in some studies, patients with orthostatic intolerance exhibited greater supine blood pressure values than age-and sex-matched control subjects (5) . The selective inhibition of norepinephrine reuptake by reboxetine has been reported to induce a slight but significant increase in blood pressure (6) . The results of previous reports that involved measurement of the whole body plasma kinetics of tritiated norepinephrine suggest that neuronal norepinephrine reuptake may be impaired in essential hypertension (9) . More direct evidence for the impaired neuronal reuptake of norepinephrine in essential hypertension has also been reported by a study using a phenotypically relevant radiotracer method (7) . Thus, SLC6A2 is a good candidate gene for human essential hypertension, and the present study showed that one of the promoter variants of SLC6A2 was associated with hypertensive status.
In this study, we analyzed five polymorphisms. The association between the Promoter 3 genotype and hypertension remained significant after multiple regression analysis with Bonferroni's correction for multiple comparisons, and thus the Promoter 3 genotype was considered useful for the prediction of hypertensive status.
It has been expected that a variant of SLC6A2 may be associated not only with blood pressure values but also with heart rate values. However, no significant effects of this genotype on heart rate were observed in this study. Heart rate and blood pressure values are both considered to be moderated by various drugs for cardiovascular diseases, including hypertension. Thus, in the present study, we excluded subjects who had received antihypertensive treatment or experienced cerebrovascular accidents, ischemic heart diseases, or atrial fibrillation from the heart rate and blood pressure value analysis. This exclusion might have blurred the effect of the Promoter 3 polymorphism on heart rate rather than blood pressure.
The sample power in this study was 0.79. This means that 79% of studies would be expected to yield a significant effect, rejecting the null hypothesis that the odds are 1.0, and suggesting that this study has adequate statistical power.
The standards of association studies have improved over the years, and it is widely anticipated that such studies will contribute to the understanding of complex traits. To date, The characteristics of the study population are summarized according to the Promoter 3 polymorphism. % Male, percentage of male subjects; Age, age of subjects (years); BMI, body mass index (kg/m 2 ); Ethanol, ethanol consumption (ml/day); % medication, percentage of subjects receiving antihypertensive medication; % CVA, percentage of subjects who have had a cerebrovascular accident; % MI, percentage of subjects who have had a myocardial infarction; % HTN, percentage of subjects with hypertension; SBP, systolic blood pressure (mmHg); DBP, diastolic blood pressure (mmHg); HR, heart rate per minute; R-SBP, residuals of SBP adjusting for sex, age, BMI, and ethanol consumption; R-DBP, residuals of DBP adjusting for sex, age, BMI, and ethanol consumption; R-HR, residuals of HR adjusting for sex. Blood pressure and HR values of subjects who were receiving cardiovascular medication were excluded. The number of subjects analyzed was 1,170 subjects with the AA genotype, 356 subjects with the AG genotype, and 33 subjects with the GG genotype. however, only a few association studies have been replicated (10) . Therefore, replication in other populations will be necessary to confirm our present observations. SLC6A2 is located at chromosome 16q12.2. CAPNS2 (calpain small subunit 2) and FLJ31547 (unknown function) have been reported to exist adjacent to SLC6A2. Moreover, the Bardet-Biedl syndrome 2 gene has also been reported to exist at this locus (11) . The distance for tight linkage disequilibrium may vary according to the chromosomal region and race, and may be beyond 50 kb (12) . In this sense, it may be necessary to sequence and genotype a wider range of this chromosomal region to identify the genetic variations that truly influence blood pressure.
